AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on Monday. The study tested the safety and efficacy of flexible doses of the drug,
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety.
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study
AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration approval of the drug in 2025. AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study.
Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, late-stage study showed that the drug significantly improved
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-2 study, which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson’s disease (PD).
CervoMed's dementia drug fails to meet mid-stage trial goals
U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial. The drug, neflamapimod,
Outsourcing-pharma1d
AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
STAT2d
AbbVie drug succeeds in another Parkinson’s trial
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers ...
Crain's Chicago Business1d
After one disappointment, AbbVie gets good news out of Cerevel buy
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
clinicaladvisor.com1d
Tavapadon Beneficial for Early Parkinson Disease in Flexible-Dose Trial
Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.